MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 05-16-2026
Myovant Sciences Ltd. EBITDA per Share 2011-2026 | MYOV
Annual EBITDA per Share Myovant Sciences Ltd.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -2 | -2.89 | -3.18 | -3.95 | -2.11 | -1.7 | -0.04 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.04 | -3.95 | -2.27 |
Quarterly EBITDA per Share Myovant Sciences Ltd.
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.53 | -0.09 | -0.54 | -0.63 | -0.34 | -0.63 | -0.64 | -0.86 | -0.79 | -0.38 | -0.87 | -0.96 | -0.79 | -0.88 | -0.88 | -1.04 | -0.98 | -0.98 | -1.04 | -0.7 | -0.51 | -0.37 | -0.7 | -0.15 | -0.82 | - | -0.15 | -1.34 | -1.29 | -0.04 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.04 | -1.34 | -0.687 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-0.71 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-0.82 | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-2.35 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
0.08 | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
-2.46 | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-2.24 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-0.03 | - | -13.47 % | $ 169 M | France |
 |
Compugen Ltd.
CGEN
|
0.34 | $ 2.22 | 1.37 % | $ 207 M |  Israel |
 |
AstraZeneca PLC
AZN
|
12.6 | - | - | $ 96.9 B |  Britain |
 |
BioNTech SE
BNTX
|
-5.81 | $ 89.59 | 1.29 % | $ 21.7 B | Germany |
 |
Coherus BioSciences
CHRS
|
-1.54 | $ 1.58 | 7.14 % | $ 185 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.22 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-23.7 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-3.51 | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
-0.04 | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
-0.03 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-0.03 | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
-0.54 | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-2.84 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-1.81 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-1.29 | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
-4.28 | $ 29.93 | 0.54 % | $ 1.99 B | USA |
 |
Generation Bio Co.
GBIO
|
-2.06 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-0.28 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-0.32 | $ 0.79 | -7.0 % | $ 36.1 M | Israel |
 |
Akouos
AKUS
|
-2.45 | - | 0.23 % | $ 488 M | USA |
 |
Esperion Therapeutics
ESPR
|
0.29 | $ 3.13 | -0.32 % | $ 651 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.42 | - | - | $ 7.46 M | Israel |
 |
Eton Pharmaceuticals
ETON
|
0.12 | $ 28.9 | 4.67 % | $ 778 M | USA |
|
Forte Biosciences
FBRX
|
-5.45 | $ 16.69 | -1.82 % | $ 216 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-3.85 | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-1.63 | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
-1.67 | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
-0.4 | $ 14.79 | 2.64 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
-5.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-3.37 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-2.22 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-3.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-6.03 | $ 3.16 | 1.61 % | $ 5.2 M | Israel |
 |
Aptose Biosciences
APTO
|
0.01 | - | -45.71 % | $ 1.2 M | Canada |
 |
CRISPR Therapeutics AG
CRSP
|
-7.17 | $ 56.95 | 9.35 % | $ 5.12 B |  Schweiz |
 |
Aptinyx
APTX
|
-0.92 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-6.41 | - | -0.23 % | $ 916 M | USA |
 |
Galectin Therapeutics
GALT
|
-0.31 | $ 2.38 | 1.28 % | $ 152 M | USA |